Gordon Mallarkey

400 total citations
22 papers, 334 citations indexed

About

Gordon Mallarkey is a scholar working on Cardiology and Cardiovascular Medicine, Pharmacology and Surgery. According to data from OpenAlex, Gordon Mallarkey has authored 22 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 5 papers in Pharmacology and 4 papers in Surgery. Recurrent topics in Gordon Mallarkey's work include Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Inflammatory mediators and NSAID effects (5 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Gordon Mallarkey is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (5 papers), Inflammatory mediators and NSAID effects (5 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Gordon Mallarkey collaborates with scholars based in United Kingdom, Australia and United States. Gordon Mallarkey's co-authors include Christopher J. Dunn, Lesley J. Scott, Miriam Sharpe, Edgardo Kaplinsky, Remo Panaccione, Gary R. Lichtenstein, R. Charles Coombes, Arduino A. Mangoni, Madlen Gazarian and Amanda Thomson and has published in prestigious journals such as British Journal of Pharmacology, Drugs and Thrombosis and Haemostasis.

In The Last Decade

Gordon Mallarkey

21 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gordon Mallarkey United Kingdom 10 81 66 62 62 52 22 334
Miriam Sharpe 7 94 1.2× 97 1.5× 110 1.8× 59 1.0× 94 1.8× 9 537
Céline Ollier France 8 78 1.0× 212 3.2× 26 0.4× 47 0.8× 32 0.6× 10 394
Hardik Shah India 8 71 0.9× 54 0.8× 15 0.2× 38 0.6× 65 1.3× 21 322
Margareth Gabrielsson Sweden 7 55 0.7× 103 1.6× 13 0.2× 41 0.7× 44 0.8× 10 348
L. Connors United States 6 143 1.8× 81 1.2× 18 0.3× 72 1.2× 39 0.8× 7 476
Seong Bok Jang South Korea 13 122 1.5× 62 0.9× 9 0.1× 27 0.4× 47 0.9× 34 387
George Perentesis United States 9 34 0.4× 33 0.5× 14 0.2× 25 0.4× 63 1.2× 21 402
J. Gerloff Germany 11 77 1.0× 44 0.7× 27 0.4× 18 0.3× 73 1.4× 21 430
Fabrice Hurbin France 10 137 1.7× 354 5.4× 53 0.9× 41 0.7× 40 0.8× 18 562
Lawrence Goldkind United States 10 105 1.3× 28 0.4× 22 0.4× 23 0.4× 66 1.3× 17 581

Countries citing papers authored by Gordon Mallarkey

Since Specialization
Citations

This map shows the geographic impact of Gordon Mallarkey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Mallarkey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Mallarkey more than expected).

Fields of papers citing papers by Gordon Mallarkey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Mallarkey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Mallarkey. The network helps show where Gordon Mallarkey may publish in the future.

Co-authorship network of co-authors of Gordon Mallarkey

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Mallarkey. A scholar is included among the top collaborators of Gordon Mallarkey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Mallarkey. Gordon Mallarkey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kosmas, Constantine E., Andreas Sourlas, Gordon Mallarkey, et al.. (2019). Therapeutic management of hyperlipoproteinemia (a). Drugs in Context. 8. 1–11. 15 indexed citations
2.
Kaplinsky, Edgardo & Gordon Mallarkey. (2018). Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs in Context. 7. 1–10. 38 indexed citations
3.
Mallarkey, Gordon & David M. Reid. (2016). Osteoporosis therapeutics: recent developments at ASBMR. Therapeutic Advances in Musculoskeletal Disease. 8(1). 3–7. 2 indexed citations
4.
Mallarkey, Gordon & Arduino A. Mangoni. (2015). Targeting precision medicine toxicity: recent developments. Therapeutic Advances in Drug Safety. 6(1). 4–14. 5 indexed citations
5.
Mallarkey, Gordon & R. Charles Coombes. (2013). Targeted therapies in medical oncology: successes, failures and next steps. Therapeutic Advances in Medical Oncology. 5(1). 5–16. 9 indexed citations
6.
Mallarkey, Gordon & R. Charles Coombes. (2011). Advancing breast cancer therapy by translational research: highlights of the Improving Care and Knowledge through Translational Research (IMPAKT) breast cancer conference. Therapeutic Advances in Medical Oncology. 3(5). 223–227. 2 indexed citations
7.
Mallarkey, Gordon, et al.. (2009). Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group. The Medical Journal of Australia. 190(8). 406–407. 1 indexed citations
8.
Mallarkey, Gordon, et al.. (2008). Accuracy of packaging of dose administration aids in regional aged care facilities in the Hunter area of New South Wales. The Medical Journal of Australia. 188(5). 280–282. 22 indexed citations
9.
Mallarkey, Gordon, et al.. (2008). An Evaluation of Eptacog Alfa in Nonhaemophiliac Conditions. Drugs. 68(12). 1665–1689. 11 indexed citations
10.
Lichtenstein, Gary R., Remo Panaccione, & Gordon Mallarkey. (2008). Review: Efficacy and safety of adalimumab in Crohn's disease. Therapeutic Advances in Gastroenterology. 1(1). 43–50. 24 indexed citations
11.
Mallarkey, Gordon. (2008). What are the therapeutic advances in neurology? Opinions from world experts. Therapeutic Advances in Neurological Disorders. 1(1). 5–12. 8 indexed citations
12.
Scott, Lesley J., Christopher J. Dunn, Gordon Mallarkey, & Miriam Sharpe. (2002). Esomeprazole. Drugs. 62(7). 1091–1118. 17 indexed citations
13.
Scott, Lesley J., Christopher J. Dunn, Gordon Mallarkey, & Miriam Sharpe. (2002). Esomeprazole. Drugs. 62(10). 1503–1538. 133 indexed citations
14.
Mallarkey, Gordon. (1999). Drug treatment considerations in the elderly. 4 indexed citations
15.
Mallarkey, Gordon, et al.. (1985). A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea‐pigs and rats. British Journal of Pharmacology. 84(2). 425–430. 17 indexed citations
16.
Mallarkey, Gordon, et al.. (1985). The Involvement of Platelets and the Coronary Vasculature in Collagen-Induced Sudden Death in Rabbits. Thrombosis and Haemostasis. 53(1). 70–74. 5 indexed citations
17.
Mallarkey, Gordon, et al.. (1984). Comparison of the actions of 11.9 epoxymethano PGH2 and 9.11 AZO PGH2 on rat aorta and stomach strip preparations. Prostaglandins. 27(1). 105–110. 1 indexed citations
18.
Mallarkey, Gordon, et al.. (1984). The effect of arachidonic acid metabolism on intravascular platelet aggregation in rats. Thrombosis Research. 36(2). 91–102. 7 indexed citations
19.
Mallarkey, Gordon, et al.. (1981). A Study Of The Mechanisms Involved In Collagen-Induced Intravascular Platelet Aggregation. Thrombosis and Haemostasis. 1 indexed citations
20.
Duncan, Gillian, et al.. (1980). A Study of the Mechanism of Collagen-Induced Intravascular Platelet Aggregation in the Rat. Journal of Pharmacy and Pharmacology. 32(Supplement_1). 105P–105P. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Sharpe Breakdown of academic impact, for papers by Céline Ollier Breakdown of academic impact, for papers by Hardik Shah Breakdown of academic impact, for papers by Margareth Gabrielsson Breakdown of academic impact, for papers by L. Connors Breakdown of academic impact, for papers by Seong Bok Jang Breakdown of academic impact, for papers by George Perentesis Breakdown of academic impact, for papers by J. Gerloff Breakdown of academic impact, for papers by Fabrice Hurbin Breakdown of academic impact, for papers by Lawrence Goldkind
Rankless by CCL
2026